



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**13<sup>th</sup> October 2016, 1pm-3pm**

**Room 3&4, Nye Bevan House, Maclure Road, Rochdale,  
OL16 1DN**

**Declarations of Interest**

(Members may be excluded from discussion/decision making where appropriate – to be recorded in minutes)

Apologies:

	<b>ENC</b>
<b>1) Draft Minutes of August 2016</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations from May 2016 meeting – approved at Sept 2016 GMMM meeting.</li> <li>b) RAG List Recommendations from June 2016 meeting – approved at Sept 2016 GMMM meeting.</li> <li>c) RAG List Recommendations from Aug 2016 meeting - comments received</li> <li>d) DMARDs in dermatology SCPs – approved at Sept 2016 GMMM meeting.</li> <li>e) Naltrexone for opioid and alcohol dependence</li> </ul>	Item 2c Item 2e
<b>3) Drugs requiring a review of RAG status</b> <ul style="list-style-type: none"> <li>• Linezolid</li> <li>• Octreotide for Acromegaly</li> <li>• Oral Ketoconazole for treatment of Cushing's disease</li> <li>• Degarelix</li> <li>• Metoject for psoriatic arthritis and psoriasis</li> </ul>	Item 3a Item 3b Item 3c Item 3d
<b>4) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>• Nivolumab</li> <li>• Ticagrelor for the long term prevention of atherothrombotic events in adult patients with a history of MI</li> <li>• Lesinurad(Zurampic®▼) for the treatment of gout</li> <li>• Brivaracetam (Briviact®▼) for the adjunctive treatment of focal onset seizures.</li> <li>• Ulipristal (Esmya®) 5mg tablets for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women.</li> </ul>	Item 4a Item 4b Item 4c Item 4d

<b>5) Shared Care Protocols – comments received</b> <ul style="list-style-type: none"> <li>• Mycophenolate mofetil for Interstitial Lung Disease</li> <li>• Guanfacine for childhood and adolescent ADHD</li> </ul>	Item 5a Item 5b
<b>6) Shared Care Protocols – 1<sup>st</sup> draft</b> <ul style="list-style-type: none"> <li>• None this month</li> </ul>	
<b>7) Paediatric Growth Hormone SCP – amendment</b>	Item 7a Item 7b
<b>8) Consultation on mechanism for GPs accepting shared care</b>	Item 8
<b>9) Survey on use of GMMMGS SCPs.</b>	Item 9
<b>10) Future Structure of GMMMGS and its Subgroups - update</b>	Item 10a Item 10b Item 10c
<b>11) GMMMGS SCPs as of 1.10.2016</b>	Item 11
<b>12) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMGS (verbal)	
<b>13) AOB</b>	
<b>Date of Next Meeting: new Pathways and shared care subgroup, November 10<sup>th</sup> 2016, HMR CCG 1pm-3pm, Croft Shifa Health Centre, Belfield Road, Rochdale, OL16 2UP</b>	